Evidence map›Paper›PMID 42566070›Full record

ReviewJournal of gastrointestinal cancer2026

Capmatinib for High-Level MET-Amplified Metastatic Gastric Cancer Identified by Comprehensive Genomic Profiling: A Case Report and Literature Review.

Yasuyoshi Sato, Kousuke Watanabe, Mana Matsuoka, Yurina Yamada, Koichi Yagi, Kuniko Sunami, Miho Ogawa, Katsutoshi Oda, Yoshifumi Baba

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yasuyoshi SatoDepartment of Clinical Oncology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. yasuyoshi_s@hotmail.com.ORCID https://orcid.org/0000-0003-4145-8694
Kousuke WatanabeDepartment of Clinical Genomics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Mana MatsuokaDepartment of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Sumida- ku, Tokyo, Japan.
Yurina YamadaDepartment of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Sumida- ku, Tokyo, Japan.
Koichi YagiDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Kuniko SunamiDepartment of Laboratory Medicine, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Miho OgawaDepartment of Clinical Genomics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Katsutoshi OdaDepartment of Clinical Genomics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Yoshifumi BabaDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-level MET gene amplification is a rare but potentially actionable alteration in gastric cancer. Previous phase III trials of MET-targeted therapies enrolled broadly MET-positive populations without prospective selection for high-level MET amplification, and no MET-directed therapy is currently established for this disease. Here, we report a 74-year-old woman with heavily pretreated metastatic gastric adenocarcinoma harboring high-level MET amplification (copy number 21) identified by comprehensive genomic profiling. Following expert panel review, the patient received capmatinib through the BELIEVE trial (NCCH1901; jRCTs031190104) and achieved a confirmed partial response at 8 weeks, with a 43.7% reduction in the sum of target lesion diameters. The response was maintained at 16 weeks; disease progression was observed at 24 weeks, with a progression-free survival of approximately 5.5 months. In the context of a literature review of MET-targeted therapies in gastric cancer, this case supports further investigation of selective MET inhibition in gastric cancer with high-level MET amplification, a rare molecular subset not prospectively enriched in previous clinical trials.

Indexed as

AdenocarcinomaAntineoplastic AgentsImidazolesProtein Kinase InhibitorsProto-Oncogene Proteins c-metStomach NeoplasmsTriazinesAgedBenzamidesFemaleGene AmplificationHumansAntineoplastic AgentsBenzamidescapmatinibImidazolesMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metTriazinesCapmatinibComprehensive genomic profilingGastric cancerMET amplificationMET-targeted therapyPrecision oncology

Identifiers

PMID42566070
PMCPMC13451227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.